Therapy Areas: Diabetes
Zucara Therapeutics commences ZT-01 phase 1b trial
29 July 2021 - Zucara Therapeutics Inc, a Canada-based diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycaemia (low blood glucose levels), a...
ForwardVue Pharma names new chief executive officer
28 July 2021 - ForwardVue Pharma, an emerging biopharmaceutical company, announced on Tuesday that it has appointed Bob Katz as its new chief executive officer.In the new role, Katz is to advance the ...
COVID-19 Study Identifies Prevalence of Unusual Symptoms in Older Adults
20 July 2021 - - While many hospitalized patients with the coronavirus disease 2019 (COVID-19) come to the hospital with symptoms of fever, cough or shortness of breath, a new large-scale study conduc...
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
19 July 2021 - - US-based biotechnology company Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has begun a Phase 2 proof-of-concept study in acute pain following bunionectomy surgery with the selecti...
Enrollment Initiated in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
19 July 2021 - - The Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the IMPROVE-HCM study, a Phase 2 study of the safety, tolerability, and...
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma to Commercialize Ogluo in Europe
19 July 2021 - - US-based specialty pharmaceutical company Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) has inked an exclusive agreement with UK-based 'niche speciality' pharmaceutical company...
Related Headlines

FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia Clinical Trial

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

FDS Amplicare awards USD25,000 grant to Community Pharmacy Enhanced Services Network Minnesota

Ildong Pharmaceutical to commence IDG16177 phase one study in Germany

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

REMD Biotherapeutics Presents Positive Top-Line Results in a Phase 2 Program of Lead Product Candidate Volagidemab in Patients with Type 1 Diabetes

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

Carmot to Receive Royalty Payments Upon Sales of Amgen's FDA Approved First-in-class KRAS G12C Inhibitor, Lumakras

Alternative Diabetes Treatment Specialist Virta Health Touts Promising Results on Mitigating COVID-19 Severity for People with Type 2 Diabetes

Investigational 2 mg Dose of Ozempic Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic 1 mg in Adults with Type 2 Diabetes in a Phase 3 Trial

Unmanaged Diabetes Associated with Greater COVID-19 Severity, Study Indicates

DARE-19 Trial Finds Dapagliflozin Well Tolerated in Hospitalized COVID-19 Patients

American Diabetes Association's clinical trial finds dapagliflozin was well tolerated in hospitalised COVID-19 patients

ADA reveals diabetes is strongest indicator of COVID-19 severity in Japanese patients

Lyndra Therapeutics Presents Preclinical Data on Once-Weekly Oral Buprenorphine Treatment, LYN-013, in Development for Opioid Use Disorder